IPSEN (OTCMKTS:IPSEY) Sees Large Volume Increase – Here’s Why

IPSEN (OTCMKTS:IPSEY) saw unusually-high trading volume on Tuesday . Approximately 29,446 shares changed hands during mid-day trading, an increase of 450% from the previous session’s volume of 5,358 shares.The stock last traded at $38.45 and had previously closed at $39.10.

Wall Street Analyst Weigh In

IPSEY has been the topic of several research analyst reports. UBS Group lowered IPSEN from a “strong-buy” rating to a “hold” rating in a research note on Thursday, January 8th. Deutsche Bank Aktiengesellschaft restated a “buy” rating on shares of IPSEN in a research report on Monday, November 3rd. Finally, BNP Paribas Exane downgraded IPSEN to an “underperform” rating in a research note on Wednesday, November 26th. One research analyst has rated the stock with a Buy rating, one has given a Hold rating and one has given a Sell rating to the company. Based on data from MarketBeat, IPSEN has an average rating of “Hold”.

IPSEN Trading Up 1.8%

The business’s fifty day moving average price is $36.38 and its 200 day moving average price is $34.42.

About IPSEN

Ipsen is a global biopharmaceutical company headquartered in Boulogne-Billancourt, France. Founded in 1929, the company focuses on specialty care areas including oncology, neuroscience and rare diseases. Ipsen develops, manufactures and commercializes innovative medicines that address critical unmet medical needs, offering a diverse portfolio of therapies for both adult and pediatric patient populations.

The company’s oncology franchise includes treatments for prostate, renal and hepatocellular carcinomas, with key products such as Cabometyx (cabozantinib) and Decapeptyl (triptorelin).